- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
UK Life Sciences Sector Sees "Resurgence" in Financing
March 16, 2015.
The UK's life sciences financings is seeing a resurgence in financing, according to a press release by BioTrinity and Peel Hunt.
114 financing rounds were disclosed in 2014 by the UK life sciences sector across a range of companies; $883m ($1,301m) was raised in venture financing rounds - of which nearly $500m ($737m) was raised by biotech companies - and $1,975m ($2,911m) was raised on the London Stock Exchange.Circassia Pharmaceuticals plc raised over £200m in March 2014, valuing the company at £581m, making it the largest ever London-listed biotech IPO.
2015 has got off to a good start in London, the press release adds, with specialty pharmaceutical company Allergy Therapeutics proposing to raise $32m and IP Group proposing to raise $192m. In addition, there is evidence of funds flowing from US-based investors into a number of London listed mid and small cap healthcare companies, signifying that London listed companies are able to attract capital on a global stage.
Further analysis of UK life sciences financings will be presented at BioTrinity 2015 (London, May 11–13) by Clare Terlouw who will represent Peel Hunt in an expert panel on May 12.
